Skip to content

    Supreme Petroch.

    SPLPETRONeutral
    Chemicals·23 Jan 2026
    Management Summary

    Supreme Petrochem reported a challenging Q3 FY26, where volume growth of 6.7% was overshadowed by a 10% revenue decline caused by a sharp drop in Styrene Monomer prices (from $1,040 to $810). The quarter was marked by a significant operational setback as the recently commissioned ABS plant was shut down in December due to a proprietary equipment malfunction. Despite this, management remains optimistic about a demand recovery in Q4 led by OEM seasonality and is proceeding with a ₹250-275 crore capex plan for the upcoming fiscal year.

    Highlights

    8
    • Revenue (Operating Income) for Q3 stood at ₹1,265 crores, a 10% YoY decline primarily due to falling Styrene Monomer (SM) prices.

    • Operating EBITDA for the quarter was ₹69 crores with a margin of 5.47%.

    • Net Profit (PAT) after exceptional items and tax was reported at ₹30 crores for Q3.

    • Sales volume of manufactured products grew to 91,265 MT in Q3, up from 85,537 MT in the previous year.

    • The newly commissioned 70,000 MTPA ABS plant faced a major setback with operations suspended in December 2025 due to critical equipment failure.

    • EPS Phase 2 expansion is on track to become operational by February or March 2026.

    • The company remains debt-free with an investible surplus of ₹463 crores as of December 31, 2025.

    • Polystyrene and EPS plants operated at high utilization levels of 80% and 87-88% respectively during the quarter.

    Concerns

    1
    • Technical failure of critical proprietary equipment at the new ABS plant.

    What Changed3

    vs Q4 FY26

    Guidance items7 → 4 (-3)Risks discussed5 → 3 (-2)Q&A highlights8 → 3 (-5)

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue₹1,265 Cr-10%YoY
    2. 02Operating EBITDA Margin5.5%
    3. 03PAT₹30 Cr
    4. 04Sales Volume91,265 MT+6.7%YoY
    5. 05Investible Surplus₹463 Cr

    Segment breakdown

    Polystyrene
    80% Capacity Utilization
    EPS
    87.5% Capacity Utilization1,60,000 tonnes p.a. Market Size (India)
    XPS
    70% Capacity Utilization
    ABS
    70,000 MTPA Installed Capacity
    List

    Guidance & targets

    4
    CategoryTargetPriority
    Capex
    Total Capex
    ₹250-275 crores
    Medium
    Volume
    Volume Growth
    10%
    Medium
    Volume
    Base Business Volume Growth
    3-4%
    Medium
    Capacity
    EPS Phase 2 Operational Timeline
    February or March 2026
    High

    Risks & concerns

    5
    RiskSeverity

    Technical failure of critical proprietary equipment at the new ABS plant.

    Operations suspended in Dec 2025; foreign consultants are on-site but no restart date is confirmed.Management acknowledged

    high

    Raw material (Styrene Monomer) price volatility.

    SM prices dropped from $1,040 to $810, shrinking margins and causing inventory destocking by customers.Both acknowledged

    medium

    Delay in IOCL Styrene Monomer plant commissioning.

    Delays in the IOCL plant will consequently delay Supreme's own Panipat plant project.Management acknowledged

    medium

    Areas of Evasion(2)

    • Segment-wise revenue/contribution numbers for ABS.
    • Specific fixed costs for the ABS facility.

    Q&A highlights

    3

    “It is a proprietary critical equipment. So, we could not have opened it here also... we have no definite answer from the team yet that by when it can be operated.”

    The ABS plant is a key growth driver; the inability to provide a restart timeline creates significant uncertainty for FY27 projections.

    asked by Nirav Jimudia

    2 min read5 chapters

    Detailed Narrative

    01

    ABS Plant Operational Setback

    The company's 70,000 MTPA ABS plant, which started production in September 2025, faced a major operational halt in December 2025. Management described the failure of a proprietary critical production equipment as an 'unfortunate incident' that has never been encountered by their technical collaborators before. While engineering consultants and equipment suppliers are on-site, there is currently no definite timeline for restarting operations, which poses a risk to the projected 7% volume contribution from this segment.

    02

    Revenue Headwinds from SM Price Deflation

    Operating income declined 10% YoY to ₹1,265 crores, primarily driven by a sharp correction in Styrene Monomer (SM) prices. Average published SM prices fell from approximately USD 1,040 in Q3 FY25 to about USD 810 in December 2025. This price drop not only reduced realizations but also led to a shrinking market as processors preferred to destock in a falling price environment.

    03

    Resilient Volume Growth in Base Business

    Despite revenue declines, sales volumes for manufactured products grew by 6.7% YoY to 91,265 MT. Polystyrene plants operated at 80% utilization, while EPS plants reached 87-88% utilization. Management noted that demand began to stabilize in late December as SM prices showed an upward bias, encouraging processors to increase offtake.

    04

    Capex and Expansion Roadmap

    Supreme Petrochem maintains a robust expansion plan, estimating a capex of ₹250 to ₹275 crores for FY27, focused on Chennai, Amdoshi, and Panipat infrastructure. The EPS Phase 2 expansion is nearing completion and is expected to be operational by February or March 2026. All capex continues to be funded through internal accruals, preserving the company's debt-free status.

    05

    Market Dynamics and Import Competition

    Management addressed concerns regarding imports, clarifying that high import volumes from China are largely reprocessed material for non-prime applications like wall panels. Prime-grade competition remains centered on imports from South Korea, Taiwan, and Thailand. The company is also eyeing the European market, hoping for a demand pickup once the India-EU FTA is signed.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.